RxDoctor Payments Data

Steven Gittler, MD

Pulmonary Disease · Hollywood, FLNPI 1730176728

Payments from drug & device makers

$1,059in general payments, 2019–2025

Across 69 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$361
  • AstraZeneca$193
  • Boehringer Ingelheim$122
  • Regeneron Healthcare Solutions, Inc.$76
  • Genentech USA, Inc.$74
  • Actelion Pharmaceuticals US, Inc.$61
  • plus $172 from 7 others

What the payments were for

  • Food & beverage$1,02196%
  • Education$384%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,059 in reported general payments places this provider in the 30th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$114,168
Medicare patients
475
Services billed
1,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate13$172,330
Trelegy ElliptaFluticasone/Umeclidin/Vilanter156$135,063
Breztri AerosphereBudesonide/Glycopyr/Formoterol117$103,161
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr109$74,724
Breo ElliptaFluticasone/Vilanterol82$45,691
Stiolto RespimatTiotropium Br/Olodaterol Hcl56$37,315
Arnuity ElliptaFluticasone Furoate40$11,875
Bevespi AerosphereGlycopyrrolate/Formoterol Fum15$9,502
SymbicortBudesonide/Formoterol Fumarate20$7,291
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$5,964
Advair DiskusFluticasone Propion/Salmeterol11$5,393
Albuterol Sulfate HfaAlbuterol Sulfate152$4,610
Roflumilast27$3,063
Ventolin HfaAlbuterol Sulfate38$2,280
Wixela InhubFluticasone Propion/Salmeterol26$1,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$361$267,353387 claims
Boehringer IngelheimOfev, Stiolto Respimat$122$209,64569 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$193$119,954152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →